Molecule: Dual-receptor agonist activating GLP-1 + Glucagon receptors
Classification: Dual incretin/glucagon metabolic peptide • Visceral fat mobilization • Anti-NASH candidate • Appetite-suppressing neuroendocrine tool
Clinical Potency: ~15–18% body weight reduction (Phase 2) • NASH histologic improvement • Deep visceral fat reduction with lean mass preservation
Second-generation advanced metabolic peptide succeeding GLP-1 mono-agonists (semaglutide) and GIP/GLP-1 duals (tirzepatide). Unique glucagon pathway enables greater energy expenditure, deeper visceral fat reduction, and thermogenesis activation.
Appetite suppression, slowed gastric emptying, enhanced insulin secretion, suppressed postprandial glucagon, reduced caloric intake.
Hepatic lipid oxidation, enhanced lipolysis, thermogenesis/metabolic rate boost, lean muscle preservation during weight loss.
Appetite suppression + increased energy expenditure. GLP-1 caloric restriction + glucagon fat burning. Broad hepatic and metabolic marker improvements.
15.4% average weight loss over 46 weeks (Phase 2). High tolerability. Effective in diabetic and non-diabetic populations.
Deep abdominal fat reductions, improved waist circumference, skeletal muscle preservation.
Significant liver fat reductions. Hepatic inflammation & fibrosis improvement (MRI-PDFF & biopsy). Anti-steatotic/anti-fibrotic via glucagon agonism.
Triglycerides, HOMA-IR, fasting insulin improvement. CRP/cytokine reduction. Cardiovascular protective potential.
Effective in GLP-1 resistant patients. Re-engages fat loss in semaglutide/tirzepatide non-responders.
| Week | Dose (mg/week) |
|---|---|
| 1–4 | 0.3 mg weekly |
| 5–8 | 0.6 mg weekly |
| 9–12 | 1.2 mg weekly |
| 13+ | 2.4–3.6 mg weekly (therapeutic) |
Obesity + visceral adiposity → Strong candidate
NAFLD / NASH → Excellent candidate
Plateaued on GLP-1 → Ideal rescue option
Concerned about muscle loss → Prefer over traditional GLP-1s
Pancreatitis history → Use caution
Pregnancy → Contraindicated
Incretin-naïve → 0.3 mg/week
GLP-1 experienced → 0.6 mg/week
Post-tirzepatide plateau → 1.2 mg/week + titration
Survodutide 2.4–3.6 mg/week + 5-Amino-1MQ + MOTS-c
Lifestyle: Caloric restriction + resistance training
Survodutide + SLU-PP-332 + REVIVE™ AM mitochondrial stack + Omega-3, berberine
Survodutide 1.2 mg+ weekly + CJC-1295/Ipamorelin + SS-31 or NAD+
Common: Nausea, fullness, constipation, fatigue. Rare: Pancreatitis, gallstones, hepatic enzyme elevation.
| Test | Frequency |
|---|---|
| CBC, CMP | Baseline, q8–12 weeks |
| Lipid panel | 12 weeks |
| HbA1c + Insulin | 12 weeks |
| Liver US / MRI-PDFF (NASH) | Baseline + q6 months |
This document is provided solely for educational and informational purposes. Survodutide (BI 456906) and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.